Adalimumab에 의한 고리육아종

Abstract

Adalimumab is the first fully humanized monoclonal anti-tumor necrosis factor alpha (TNF-α) antibody. This drug has been shown to be of benefit in patients with inflammatory diseases in which TNF-α is involved, such as rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and Crohn’s disease. As the use of adalimumab is becoming more widespread, cutaneous side effects are being increasingly reported. Various dermatologic adverse events have been reported in the literature, including injection site reactions, psoriasis-like eruption and pityriasis rosea. Herein, we describe a case of GA associated with adalimumab treatment for adult-onset Still’s disease, which has not been reported in Korea.